Mollard, Alexis,Warner, Steven L.,Flynn, Gary A.,Vankayalapati, Hariprasad,Bearss, David J.
申请号：
AU2020223731
公开号：
AU2020223731A1
申请日:
2020.08.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020223731A120200917.pdf#####C: Users kzh AppDat Local TempinMailX i 0015 a U i Absact - 35518948.DOCX-1/l 1/2018 ABSTRACT Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): Re X" R 7 R6 R 3 (R 5+1NN R2 IR R 4 (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, 1 2 3 4 5 6 7 8 wherein R , R2, R', , R, R, R, R, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.WO 2014/151871 PCT/US2014/026595 1/5 1.2 0 5 1 Cn U) C0.8 x - 0.6 ->；0.2 T 0.20 ry 0 No ... Drug No.7 No.4 No.10 No.20 No.12 No.11 No.23 HEPG2 cells treated with 1pM compound FIG.1 1.4 1.2 0 *~ 1 0.8 UNo.4 0.6 O No.12 0.4M 0.2 DMSO 3uM luM .3uM FIG. 2
